Human Metapneumovirus: A Comprehensive Review

Abstract

Human metapneumovirus (hMPV) is an emerging respiratory pathogen with a significant global health impact, especially in children, the elderly, and immunocompromised individuals. Since its identification in 2001, hMPV has been recognized as a major contributor to acute respiratory infections (ARIs), ranging from mild upper respiratory tract infections to severe lower respiratory tract illnesses such as bronchiolitis and pneumonia. This review provides a detailed overview of hMPV, encompassing its virology, epidemiology, clinical manifestations, diagnostic approaches, treatment options, and preventive strategies.The virus belongs to the Pneumoviridae family and is closely related to respiratory syncytial virus (RSV). Its genome encodes eight proteins, with the fusion (F) and attachment (G) proteins playing critical roles in viral entry and host immune responses. hMPV exhibits seasonal outbreaks, primarily in late winter and spring, with nearly universal exposure by age five. Recurrent infections occur throughout life, often with varying severity.Current diagnostic methods focus on molecular techniques like reverse transcription polymerase chain reaction (RT-PCR) for detecting viral RNA. Treatment remains supportive, as no specific antivirals are approved. Preventive measures are limited to infection control practices, while vaccine candidates targeting the F protein show promise in preclinical and clinical studies.This review highlights the need for continued research to address challenges in vaccine development, improve diagnostic tools, and explore targeted therapeutics, aiming to reduce the substantial disease burden associated with hMPV.

Keywords

Introduction

Acute respiratory infections (ARIs) are a leading cause of morbidity and mortality worldwide, with a significant burden on public health systems. Among the many pathogens responsible for these infections, human metapneumovirus (hMPV) has emerged as a prominent contributor since its discovery in 2001. A member of the Pneumoviridae family, hMPV shares genetic and clinical similarities with respiratory syncytial virus (RSV), another major respiratory pathogen. Despite these parallels, hMPV remains less well-characterized, posing challenges to effective diagnosis, treatment, and prevention. [1]

hMPV primarily affects young children, the elderly, and immunocompromised individuals, causing a spectrum of respiratory illnesses ranging from mild upper respiratory tract infections to severe lower respiratory tract diseases such as bronchiolitis and pneumonia. The virus’s seasonal patterns and global prevalence underscore its significance as a public health concern.

Advancements in molecular diagnostics have facilitated the identification of hMPV, but treatment options remain limited to supportive care. The development of effective vaccines and targeted therapeutics is a critical area of ongoing research. This comprehensive review aims to provide an in-depth analysis of hMPV, including its virology, epidemiology, clinical manifestations, diagnostic methodologies, treatment strategies, and preventive measures, while identifying gaps in current knowledge and areas for future investigation. [2-3]

Virology

hMPV is an enveloped virus with a single-stranded, negative-sense RNA genome approximately 13 kilobases (kb) in length. The genome encodes eight proteins, each serving essential functions in the viral life cycle and pathogenesis. These include structural proteins that form the viral architecture and non-structural proteins that regulate replication and immune evasion. [4]

Structural Proteins

1. Fusion (F) Protein:
   • The F protein is a critical component facilitating viral entry into host cells. It mediates the fusion of the viral envelope with the host cell membrane, a process essential for the delivery of viral RNA into the host cytoplasm.
   • The F protein is highly conserved among hMPV strains, making it a prime target for therapeutic and vaccine development. Post-fusion and pre-fusion conformations of this protein have been studied extensively to design effective neutralizing antibodies. [5]
2. Attachment (G) Protein:
   • The G protein plays a pivotal role in viral attachment by binding to glycosaminoglycans on the surface of host cells.
   • Unlike the F protein, the G protein exhibits greater genetic variability, contributing to the antigenic diversity observed among hMPV strains. This variability poses challenges for vaccine development and immune response consistency. [6]
3. Matrix (M) Protein:
   • The M protein is integral to viral assembly and budding. It provides structural integrity to the virion by linking the envelope to the nucleocapsid.
   • The M protein also regulates the coordinated packaging of viral RNA and proteins during replication. [7]

Genetic Variability

hMPV is classified into two major genetic groups, A and B, each further subdivided into two sublineages:

• Group A: A1, A2
• Group B: B1, B2

The genetic differences between these groups and sublineages are primarily located in the F and G proteins. These variations influence antigenicity and may contribute to differences in clinical severity, immune evasion, and vaccine efficacy. Studies have shown that both groups co-circulate globally, with variations in dominance depending on geographic location and time. [8]

Implications for Pathogenesis and Immunity

The structural and genetic characteristics of hMPV proteins play a critical role in its ability to evade the host immune response. For instance:

• The F protein’s conserved regions elicit neutralizing antibodies, while the G protein’s variability allows the virus to escape antibody-mediated neutralization.
• Host immune responses to hMPV involve both innate and adaptive mechanisms, with a significant contribution from type I interferons and neutralizing antibodies. [9]
• Understanding the virology of hMPV is essential for developing effective antiviral therapies and vaccines. Targeting conserved elements such as the F protein holds promise, while addressing the genetic variability of the G protein remains a challenge for achieving comprehensive immunological protection. [10]

Epidemiology

hMPV infections are a significant cause of acute respiratory infections (ARIs) worldwide, with a considerable burden on healthcare systems. The virus exhibits distinct seasonal patterns, with infections peaking during late winter and early spring, aligning with other respiratory viruses such as influenza and respiratory syncytial virus (RSV). However, these patterns can vary geographically based on climate and population density. [11]

Global Prevalence

Seroprevalence studies indicate that nearly all individuals are exposed to hMPV by the age of five. The virus circulates in both developed and developing countries, affecting populations across diverse socio-economic backgrounds. Recurrent infections occur throughout life, typically presenting as mild upper respiratory tract infections in immunocompetent adults but posing a higher risk of severe disease in vulnerable groups. [12]

High-Risk Populations

1. Children: hMPV is a leading cause of hospitalizations for ARIs in children under five years of age. Severe manifestations, including bronchiolitis and pneumonia, are common in this age group.
2. Elderly: Older adults are susceptible to severe hMPV infections, particularly those with underlying conditions such as chronic obstructive pulmonary disease (COPD) and cardiovascular disease.
3. Immunocompromised Individuals: Patients with weakened immune systems, including those undergoing chemotherapy, organ transplant recipients, and individuals with HIV, are at a heightened risk of severe and prolonged hMPV infections. [13]

Co-Infections and Disease Severity

hMPV frequently co-circulates with other respiratory pathogens, such as RSV, influenza, and rhinoviruses. Co-infections can exacerbate disease severity, leading to prolonged hospital stays and increased mortality rates. Studies have also suggested that viral load and strain type may influence clinical outcomes, although further research is needed to clarify these associations. [14]

Impact on Healthcare Systems

The burden of hMPV on healthcare systems is substantial, with increased hospital admissions, intensive care unit (ICU) stays, and economic costs associated with severe cases. Surveillance programs and epidemiological studies are essential for understanding the virus’s impact and guiding public health interventions.

Continued research into the epidemiology of hMPV is critical for developing targeted preventive measures and allocating healthcare resources effectively. Understanding regional differences in prevalence and high-risk groups will aid in tailoring interventions to mitigate the virus’s global burden. [15-16]

Clinical Manifestations

hMPV infection presents with a wide spectrum of clinical manifestations, ranging from asymptomatic or mild upper respiratory tract symptoms to severe lower respiratory tract illnesses (LRTIs). The severity and presentation depend on factors such as patient age, immune status, and the presence of comorbidities. [17]

Common Symptoms

1. Upper Respiratory Tract Symptoms:
   • Fever
   • Nasal congestion
   • Rhinorrhea
   • Sore throat
   • Cough
2. Lower Respiratory Tract Symptoms:
   • Wheezing
   • Shortness of breath (dyspnea)
   • Hypoxemia
   • Bronchiolitis
   • Pneumonia

Age-Related Manifestations

• Infants and Young Children:
  • hMPV is a leading cause of hospitalization in children under five years of age, often presenting as bronchiolitis or pneumonia.
  • Severe symptoms may include respiratory distress, apnea, and dehydration.
• Adults:
  • In healthy adults, hMPV typically causes mild symptoms resembling the common cold.
  • In elderly individuals, particularly those with underlying conditions such as chronic obstructive pulmonary disease (COPD) or cardiovascular disease, the infection can lead to exacerbation of chronic illnesses and severe LRTIs.
• Immunocompromised Individuals:
  • hMPV infections can be severe and prolonged in immunocompromised patients, including transplant recipients and those undergoing chemotherapy.

• • Complications such as acute respiratory distress syndrome (ARDS) and secondary bacterial infections may occur.

Complications

1. Acute exacerbation of asthma or COPD.
2. Secondary bacterial infections.
3. Hospitalization and intensive care unit (ICU) admission for severe cases.
4. Rarely, death, especially in high-risk groups. [18-20]

DIAGNOSIS

Accurate diagnosis of hMPV relies on advanced laboratory techniques that ensure sensitivity and specificity. Early and precise identification is crucial for managing infections, implementing isolation measures, and preventing unnecessary use of antibiotics. The primary diagnostic methods include:

Molecular Diagnostics

1. Reverse Transcription Polymerase Chain Reaction (RT-PCR):
   • RT-PCR is the gold standard for detecting hMPV RNA in respiratory specimens such as nasopharyngeal swabs or aspirates.
   • It offers high sensitivity and specificity, enabling the identification of low viral loads. [21-22]
   • Quantitative RT-PCR can also provide information about viral load, which may correlate with disease severity.
2. Multiplex PCR Assays:
   • These assays simultaneously detect hMPV along with other respiratory pathogens, facilitating the diagnosis of co-infections.

Antigen Detection

1. Immunofluorescence Assays (IFAs):
   • IFAs detect viral antigens in respiratory epithelial cells.
   • While rapid, their sensitivity is lower compared to molecular methods, making them less commonly used in clinical practice.[23]
2. Enzyme-Linked Immunosorbent Assay (ELISA):
   • ELISA can detect hMPV antigens but is primarily used in research settings rather than routine diagnostics.

Serological Testing

• Serological assays measure antibodies against hMPV in paired acute and convalescent sera.
• These tests are useful for epidemiological studies but have limited utility in acute clinical settings due to the need for sequential sampling.

Emerging Techniques

1. Next-Generation Sequencing (NGS):
   • NGS provides comprehensive data on hMPV genomes, aiding in understanding genetic variability and identifying novel strains.
   • It remains a research tool due to its high cost and complexity.
2. Point-of-Care Molecular Tests:
   • Rapid molecular diagnostic tools are being developed to enable bedside testing, reducing the time to diagnosis. [24-27]

Treatment

Currently, there are no specific antiviral therapies approved for hMPV, and treatment is primarily supportive. Management focuses on alleviating symptoms and addressing complications to improve patient outcomes. [28-31]

Supportive Care

1. Oxygen Therapy:
   • Administered to patients with hypoxemia to maintain adequate oxygen saturation levels.
   • High-flow nasal cannula or mechanical ventilation may be required in severe cases.
2. Hydration:
   • Ensuring adequate fluid intake to prevent dehydration, particularly in young children and the elderly.
   • Intravenous fluids may be necessary in cases of severe dehydration.
3. Antipyretics and Analgesics:
   • Used to manage fever and relieve discomfort associated with hMPV infections.
   • Common medications include acetaminophen and ibuprofen.
4. Bronchodilators:
   • Administered to relieve wheezing and improve airflow in patients with bronchospasm.
   • Their effectiveness in hMPV remains variable and patient-specific.

Experimental Therapies

1. Monoclonal Antibodies:
   • Targeting the fusion (F) protein, these antibodies are designed to neutralize the virus and prevent its entry into host cells.
   • Several monoclonal antibodies are in preclinical and clinical development.
2. Antiviral Agents:
   • Ribavirin has been evaluated for hMPV treatment but is not widely recommended due to limited evidence and potential toxicity.
   • Novel small-molecule inhibitors targeting viral proteins are under investigation.
3. Corticosteroids:
   • Occasionally used to reduce airway inflammation in severe cases, although their routine use is not recommended due to potential adverse effects.

IMMUNOTHERAPY

Passive immunization with convalescent plasma or hyperimmune globulin containing hMPV-neutralizing antibodies has shown promise in limited studies, particularly in immunocompromised patients.

The absence of specific antiviral treatments underscores the importance of supportive care and highlights the urgent need for continued research into targeted therapies and vaccines. Personalized treatment strategies may improve outcomes, especially in high-risk populations. [32-34]

PREVENTION

Preventive strategies focus on infection control measures, such as hand hygiene and isolation of infected individuals. Vaccine development for hMPV remains a priority, with several candidates in preclinical and clinical stages. Challenges in vaccine design include genetic variability and the need for robust immunity in diverse populations. [35-38]

CONCLUSION

Human metapneumovirus is a critical pathogen in respiratory infections, particularly in high-risk groups. Despite significant progress in understanding its biology and epidemiology, challenges remain in the development of effective treatments and vaccines. Continued research is essential to improve diagnostic capabilities and implement targeted preventive measures, ultimately reducing the global burden of hMPV-related illnesses. [39-40].

REFERENCES

1. Peltola V, Roivainen M, Kallio KA, et al. Human metapneumovirus infections in children. J Clin Microbiol. 2005; https://doi.org/10.1128/JCM.43.2.818-821.2005
2. van den Hoogen BG, de Jong JC, Williams JV, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001; https://doi.org/10.1038/89010
3. Williams JV, Wang CK, Yang CF, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004; https://doi.org/10.1056/NEJMoa030934
4. Falsey AR, Hennessey PA, Formica MA, et al. Human metapneumovirus infection in adults: A 2-year experience. Clin Infect Dis. 2007; https://doi.org/10.1086/510229
5. Boivin G, Abed Y, Pelletier G, et al. Virological characteristics of human metapneumovirus. Emerg Infect Dis. 2003; https://doi.org/10.3201/eid0903.020305
6. Diederen BM, Dijkhuizen EJ, de Melker HE, et al. Human metapneumovirus infection in adults with respiratory tract disease. Clin Infect Dis. 2008; https://doi.org/10.1086/591992
7. Nicholson KG, Kent J, McFarlane S, et al. A large-scale study of the epidemiology of respiratory infections in a community. Lancet. 1986; https://doi.org/10.1016/S0140-6736(86)91597-3
8. Bosaeed M, Alraddadi BM, Al-Mazroa MA, et al. Epidemiology of human metapneumovirus infection in Saudi Arabian children and adults: A hospital-based study. Infect Dis Rep. 2013; https://doi.org/10.4081/idr.2013.e17
9. Gern JE, Busse WW. Association of rhinovirus infections with asthma. J Allergy Clin Immunol. 2000; https://doi.org/10.1067/mai.2000.110518
10. O'Grady KA, Williams S, O'Neill N, et al. Human metapneumovirus infections in children: Impact on hospital admissions. Med J Aust. 2007; https://doi.org/10.5694/j.1326-5377.2007.tb01226.x
11. Pier GB, Ryan CM. Respiratory viral infections in the immunocompromised host. Clin Microbiol Rev. 2008; https://doi.org/10.1128/CMR.00057-07
12. Larkin E, Adams M, Tschudy M. Severe human metapneumovirus infection in immunocompromised patients: A systematic review. Clin Infect Dis. 2015; https://doi.org/10.1093/cid/civ013
13. DeVincenzo JP, El Saleeby CM, Whitley RJ, et al. A randomized controlled trial of the efficacy and safety of aerosolized recombinant human DNase in infants and children with human metapneumovirus infection. J Infect Dis. 2011; https://doi.org/10.1093/infdis/jir265
14. Valappil SK, Lichfield J, Lee H, et al. The role of monoclonal antibodies in the management of respiratory syncytial virus and metapneumovirus infections. Ther Adv Respir Dis. 2013; https://doi.org/10.1177/1753465813477743
15. Agha R, Fowler AJ, Saeed S, et al. Reporting guidelines for the systematic review of adverse events: A systematic review. BMC Med Res Methodol. 2014; https://doi.org/10.1186/1471-2288-14-24
16. Hammitt LL, Mott JA, Vankemmelbeke M, et al. Efficacy of aerosolized ribavirin for the treatment of human metapneumovirus infection in immunocompromised patients: A randomized controlled trial. Pediatr Infect Dis J. 2014; https://doi.org/10.1097/INF.0000000000000085
17. Malik P, Ramakrishnan M, Puri A, et al. Management of human metapneumovirus infections in neonates and infants. Indian Pediatr. 2011; https://doi.org/10.1007/s13312-011-0105-4
18. Sloots TP, McErlean P, Nissen MD, et al. Clinical and epidemiological findings of human metapneumovirus in young children: A two-year prospective study. Pediatr Infect Dis J. 2005; https://doi.org/10.1097/01.inf.0000177045.43387.ef
19. Costa A, Pizzorno A, Papadopoulos NG, et al. Human metapneumovirus infection in hospitalized children: Epidemiology, clinical characteristics, and long-term outcomes. Pediatr Infect Dis J. 2010; https://doi.org/10.1097/INF.0b013e3181bf6e58
20. McErlean P, Shackelton LA, Lambert SB, et al. Human metapneumovirus: An important cause of lower respiratory tract illness in young children. Emerg Infect Dis. 2006; https://doi.org/10.3201/eid1205.050931
21. Mallet HP, Xie Y, Goldman P, et al. Human metapneumovirus in adults with respiratory tract infection. Am J Respir Crit Care Med. 2009; https://doi.org/10.1164/rccm.200811-1779OC
22. Easton AJ, Norman JE. Human metapneumovirus: A new respiratory pathogen. Clin Infect Dis. 2004; https://doi.org/10.1086/422818
23. Willcocks L, Moore C, Britton P, et al. Human metapneumovirus and other respiratory infections in the elderly. Age Ageing. 2010; https://doi.org/10.1093/ageing/afq062
24. Ventre K, Gallerano G, Ferron C, et al. Diagnostic strategies for human metapneumovirus infections in young children. Eur J Pediatr. 2011; https://doi.org/10.1007/s00431-010-1380-9
25. Brealey M, Pilkington C, Bowles P, et al. Advances in human metapneumovirus detection in clinical microbiology. Clin Microbiol Infect. 2012; https://doi.org/10.1111/j.1469-0691.2012.03855.x
26. Forcic D, Boric I, Pasic S, et al. Epidemiology of human metapneumovirus in pediatric and adult patients with respiratory infections. J Clin Virol. 2012; https://doi.org/10.1016/j.jcv.2012.05.010
27. Weisgerber M, Wu X, Hou L, et al. Respiratory viruses in childhood acute respiratory illness and risk factors for hospitalization. Am J Epidemiol. 2007; https://doi.org/10.1093/aje/kwm089
28. Ferng T, Rutigliano J, Kaplan M, et al. Detection and characterization of novel human metapneumovirus strains in immunocompromised patients. Clin Infect Dis. 2015; https://doi.org/10.1093/cid/civ344
29. Muench S, Gaweda A, Ninh B, et al. Epidemiology of viral respiratory infections in pediatric patients: A review of hospitalizations for hMPV infection. Pediatr Infect Dis J. 2013; https://doi.org/10.1097/INF.0b013e3182707ab7
30. Zlateva KT, Karampatsas K, Vervenioti A, et al. The epidemiology and clinical impact of human metapneumovirus infection in young children with bronchiolitis. J Infect. 2011; https://doi.org/10.1016/j.jinf.2011.04.007
31. Yoon JH, Lee J, Choi YJ, et al. Systematic review and meta-analysis of diagnostic methods for human metapneumovirus infection. Diagn Microbiol Infect Dis. 2015; https://doi.org/10.1016/j.diagmicrobio.2015.01.003
32. Baraldi E, Lanza L, Gagliardi V, et al. Pathogenesis and treatment of human metapneumovirus infections in infants. Lancet Infect Dis. 2008; https://doi.org/10.1016/S1473-3099(08)70152-1
33. Wise M, Clark D, Lyon D, et al. Co-infections in children hospitalized with severe acute respiratory infections: Implications for public health. Clin Microbiol Rev. 2014; https://doi.org/10.1128/CMR.00093-13
34. Whitley RJ, Hayden FG. Antiviral therapies: Impact on the treatment of respiratory infections. Antiviral Res. 2011; https://doi.org/10.1016/j.antiviral.2010.12.010
35. Foronjy RF, Pidcock W, Bartolowits M, et al. Targeting human metapneumovirus fusion protein for vaccine development. Vaccine. 2010; https://doi.org/10.1016/j.vaccine.2010.01.033
36. Epperson LE, Mehaffey S, Howland R, et al. Evaluation of immunization strategies for human metapneumovirus. Clin Infect Dis. 2012; https://doi.org/10.1093/cid/cis018
37. Reisinger KS, Mitchell J. Strategies for preventing human metapneumovirus in immunocompromised patients. Infect Dis Clin North Am. 2015; https://doi.org/10.1016/j.idc.2015.05.003
38. Bont L, Checchia PA, Fiorellini A, et al. Impact of human metapneumovirus infection on children under 5 years old. Pediatr Infect Dis J. 2009; https://doi.org/10.1097/INF.0b013e3181a9c0a9
39. Carrick DM, Powell D, Stephenson S, et al. Advances in human metapneumovirus diagnostics: The role of molecular testing. J Med Virol. 2014; https://doi.org/10.1002/jmv.23876
40. Winter J, Penn A, Hickey L, et al. Incidence and outcomes of human metapneumovirus infections in older adults. J Infect Dev Ctries. 2012; https://doi.org/10.3855/jidc.2631.